High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.
about
New pandemics: HIV and AIDS, HCV and chronic hepatitis, influenza virus and fluNucleic acid template and the risk of a PCR-Induced HIV-1 drug resistance mutationFactors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP)K65R in subtype C HIV-1 isolates from patients failing on a first-line regimen including d4T or AZT: comparison of Sanger and UDP sequencing dataIncreased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in CambodiaPotential impact of antiretroviral chemoprophylaxis on HIV-1 transmission in resource-limited settingsClinical and genotypic findings in HIV-infected patients with the K65R mutation failing first-line antiretroviral therapy in NigeriaThe K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics: Mumbai, India.A template-dependent dislocation mechanism potentiates K65R reverse transcriptase mutation development in subtype C variants of HIV-1Effects of the W153L substitution in HIV reverse transcriptase on viral replication and drug resistance to multiple categories of reverse transcriptase inhibitors.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C.Characterizing the emergence and persistence of drug resistant mutations in HIV-1 subtype C infections using 454 ultra deep pyrosequencingSuboptimal adherence associated with virological failure and resistance mutations to first-line highly active antiretroviral therapy (HAART) in Bangalore, India.Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.HIV Genetic Diversity and Drug Resistance.HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programmeSubtype-specific analysis of the K65R substitution in HIV-1 that confers hypersusceptibility to a novel nucleotide-competing reverse transcriptase inhibitor.Pre-exposure prophylaxis and antiretroviral resistance: HIV prevention at a cost?The use of preexposure treatments for HIV prophylaxisThe HIV-1 epidemic: low- to middle-income countries.The Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.Tenofovir in second-line ART in Zambia and South Africa: collaborative analysis of cohort studiesComparative analysis of drug resistance among B and the most prevalent non-B HIV type 1 subtypes (C, F, and CRF02_AG) in Italy.QSAR based therapeutic management of M. tuberculosis.Virological outcome and patterns of HIV-1 drug resistance in patients with 36 months' antiretroviral therapy experience in CameroonLow rates of nucleoside reverse transcriptase inhibitor resistance in a well-monitored cohort in South Africa on antiretroviral therapyHIV-1 drug resistance mutations: an updated framework for the second decade of HAARTDrug resistance mutation profile and accumulation kinetics in human immunodeficiency virus-positive individuals infected with subtypes B and F failing highly active antiretroviral therapy are influenced by different viral codon usage patterns.Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs.The challenge of HIV-1 subtype diversity.Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionNucleoside and nucleotide analogs select in culture for different patterns of drug resistance in human immunodeficiency virus types 1 and 2.Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel.Reverse transcriptase inhibitors as potential colorectal microbicides.Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.Differences in resistance mutations among HIV-1 non-subtype B infections: a systematic review of evidence (1996-2008)Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India
P2860
Q27478093-E1C258B0-9E95-4706-9BC0-1DFB0E3C6EC2Q28474274-298BE907-455A-4C7B-8AEC-F5CB1ADC19A4Q28477780-697A0F73-F162-4B48-91C4-7A4FDD4ED5A8Q28483758-2441ABE2-3A7B-420A-9F80-F170F86D6589Q28535850-F87144F4-2CC5-44FE-A056-87E758FD0589Q33299456-B0FA935F-253A-4219-8849-38B8C05937FAQ33625367-9668624B-6607-4DFB-A4D0-295D7B660227Q33681279-ADA98147-CC04-44B0-AF83-0D9209DBC109Q33807513-C759E3B0-1308-4AB2-8533-D3C9CE61D89AQ33927293-77E0F06C-1157-42C3-8D24-518FAE16FA53Q34058254-2C387B2B-FD80-4BA6-A2B3-12F7405C3E15Q34303603-72BBBC13-320A-4D83-8E07-8D8526EDACC9Q34489239-369FB77E-ACC0-4A9F-84A8-B6AB96CD1EB9Q34567556-5751754E-9331-495C-AB9F-FC68C01D66FCQ34812918-5CFA024C-59A5-49E2-920B-FC8FAD909366Q34933329-971CA4F2-BF79-440E-A7BC-6C40F0AE4CFCQ35260403-AB4F0D61-1952-4B6C-A3BB-70F01B71E28DQ35260590-1F8EF011-A759-4B63-B5C5-93D499E9D212Q35536296-56900CA7-CFC4-4273-AF40-57D88B72D47EQ35607740-0E8960B0-42C7-4910-9B21-7C71DC1DCAC1Q35636514-8CC09A67-CD4C-4AC7-965B-F28703F4778BQ35760180-516DE740-43BF-4377-B4EF-541D99F84E2DQ35765737-AA6659D7-9083-4E35-9546-58FCDA5DEC77Q36077418-D37C95E5-DF40-4851-B8E6-E632CA708083Q36204098-886B0996-B40A-444B-8817-6B777E2591A0Q36250342-ECE4A158-1FBB-46DB-9327-8AFE0E9A31B8Q36359056-667E4B62-7446-4A8D-BE47-E847C723D261Q36581795-E750EF24-064F-4374-AC33-CCED0B9BDDCFQ36693481-6FCA54A1-81D7-4DC7-98F9-8BD3FC9CD602Q36900010-CA262CC3-E1FD-41AB-B33D-8A120B0883BFQ36993546-BA3AB2D5-4A74-463C-A58E-D92F19171917Q37003938-A172F264-6390-400B-BB9F-F8A6F50AECF3Q37038453-74F6AA4B-42B7-4633-AC40-E999522D4EDBQ37071435-633E059A-FDB7-46E1-BE0E-9B2C84C608B6Q37072022-91858C1D-4566-45A8-8C93-3F8FD5C48232Q37189622-2EAA7C23-C64B-4478-9438-8295DEEACE72Q37190754-447BE026-3854-478D-8EEF-C6291EA43B83Q37216229-89FF59E6-18BD-46CC-BD3A-72E0137AA47FQ37268341-377CC5CF-5FC3-4A9D-98BF-D06E3989FA9CQ37276430-F5160898-8571-45E5-8E00-5C4B17435BE4
P2860
High prevalence of the K65R mutation in human immunodeficiency virus type 1 subtype C isolates from infected patients in Botswana treated with didanosine-based regimens.
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@ast
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@en
type
label
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@ast
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@en
prefLabel
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@ast
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@en
P2093
P2860
P356
P1476
High prevalence of the K65R mu ...... ith didanosine-based regimens.
@en
P2093
Ava Avalos
Bluma Brenner
Daniella Moisi
Florence Doualla-Bell
Howard Moffat
Madisa Mine
Mark A Wainberg
Maureen Oliveira
Ndwapi Ndwapi
Tendani Gaolathe
P2860
P304
P356
10.1128/AAC.00714-06
P407
P577
2006-10-02T00:00:00Z